180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a research report released on Wednesday morning,Weiss Ratings reports.

180 Life Sciences Stock Down 2.3 %

NASDAQ:ATNF opened at $1.25 on Wednesday. The firm’s fifty day moving average is $1.63 and its two-hundred day moving average is $2.11. 180 Life Sciences has a one year low of $1.16 and a one year high of $17.75.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC purchased a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned about 2.20% of 180 Life Sciences at the end of the most recent reporting period. Institutional investors and hedge funds own 4.07% of the company’s stock.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.